SPOTLIGHT -
Understanding Patient Characteristics of Phase 3 APOLLOE4 Trial of ALZ-801 in Alzheimer Disease: John Hey, PhD
The chief scientific officer at Alzheon provided insight on the preliminary imaging findings of patients enrolled in the phase 3 APOLLOE4 study assessing ALZ-801 as a potential treatment for Alzheimer disease. [WATCH TIME: 3 minutes]